Article

ED after prostate cancer treatment may be underreported

Las Vegas-Researchers don't agree on how to measure erectile function and dysfunction, making it difficult to determine the effects of prostate cancer treatment on patients' sex lives, said Johns Hopkins researchers who presented a review of 592 articles at the Sexual Medicine Society of North America fall meeting here.

Related Videos
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
Study findings highlight gender gaps in oncology authorship and citation
NMIBC Treatment Decisions in the Age of BCG Shortages
NMIBC Treatment Decisions in the Age of BCG Shortages
Current Standards of Care and Shifting Strategies in NMIBC
Current Standards of Care and Shifting Strategies in NMIBC
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
BLUES trial: Silicone stents may improve patient care
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
1 expert is featured in this series.
Targeted Therapy in mHSPC: Effects of Mutation Absence
Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
Related Content
Medically accurate illustration of kidney cancer | Image Credit: © Crystal light - stock.adobe.com
June 1st 2025

Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment

Silas Inman
"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Perioperative sacituzumab govitecan/pembro yields compelling CR rate in MIBC
May 31st 2025

Perioperative sacituzumab govitecan/pembro yields compelling CR rate in MIBC

Hannah Clarke
The cCR rate was 44.4% in the intent-to-treat population.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
May 30th 2025

PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology

Benjamin P. Saylor
The addition of Ra223 to enzalutamide was associated with a 31% reduction in the risk of progression or death compared with enzalutamide alone.
Phase 2 trial launches of combination immunotherapy for mCRPC
May 30th 2025

Phase 2 trial launches of combination immunotherapy for mCRPC

Hannah Clarke
The trial plans to enroll approximately 70 patients with mCRPC.
© 2025 MJH Life Sciences

All rights reserved.